Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB)
Authors:
Open Access
- 18 March 2019
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-15
Abstract
Background. Breast cancer (BC) is one of the most common malignant tumors in women around the world. Atorvastatin (ATO) was found to be associated with a decreased risk of recurrence and mortality in cancer. But the exact mechanism of its carcinostatic effects is unclear. The expression level of Ras homolog family member B (RhoB) in breast cancer cells was found to be upregulated after being treated with ATO. Thus, we conjecture that altered expression of RhoB induced by ATO may be decisive for the migration and progression of breast cancer. Methods. The effects of ATO on breast tumor cells in vivo and in vitro were detected by clone formation assay, CCK-8 assay, flow cytometry, wound healing, transwell assays, tumor xenograft model, and immunohistochemistry. Distribution of RhoB in different breast cancer tissues and its influence on prognosis were analyzed using the data from TCGA or GEO databases. The relationship between RhoB and PTEN/AKT pathway was detected by Western blotting and RT-qPCR. Results. ATO inhibits proliferation, invasion, EMT, and PTEN/AKT pathway and promotes apoptosis in breast tumor cells. In addition, ATO inhibits the volume and weight of breast tumor in tumor-bearing mice and upregulated RhoB in tumor tissues. The expression of RhoB in mRNA and protein level was upregulated in statin-treated breast cancer cells and downregulated in cancer tissues. Low expression of RhoB links with poor prognosis in patients with breast cancer (HR = 0.74[0.66–0.83], p =7e−8, log-rank test). Further research found that RhoB inhibits the proliferation, invasion, EMT, and PTEN/AKT signal pathway in breast tumor cells. Conclusions. The exact mechanism of ATO’s carcinostatic effects in breast cancer is related to downregulating PTEN/AKT pathway via promoting RhoB. Our study also demonstrates the potential applicability of RhoB as a therapeutic target for breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81472765, 2015CFA070)
- Key Project of Science and Technology Department of Hubei Province (81472765, 2015CFA070)
This publication has 34 references indexed in Scilit:
- The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analysesInternational Journal of Molecular Medicine, 2012
- The differential effects of statins on the metastatic behaviour of prostate cancerBritish Journal of Cancer, 2012
- Total Cholesterol and Cancer Risk in a Large Prospective Study in KoreaJournal of Clinical Oncology, 2011
- A distinct role of RhoB in gastric cancer suppressionInternational Journal of Cancer, 2010
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- In vivo restoration of RhoB expression leads to ovarian tumor regressionCancer Gene Therapy, 2008
- Statin-Induced Inhibition of MCF-7 Breast Cancer Cell Proliferation is Related to Cell Cycle Arrest and Apoptotic and Necrotic Cell Death Mediated by an Enhanced Oxidative StressCancer Investigation, 2008
- Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate PathwayClinical Cancer Research, 2006
- Atorvastatin: A potential chemopreventive agent in bladder cancerUrology, 2005
- Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and MetastasisMolecular and Cellular Biology, 2004